Prot #CAAA617C12301: PSMAddition: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard of Care, Versus Standard of Care Alone, in Adult Male Patients with Metastatic Hormone Sensitive P

Project: Research project

Project Details

StatusActive
Effective start/end date2/9/22 → 11/21/25

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CAAA617C12301)